




Ifw

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: May 3, 2007

Signature:

  
(Sharon M. Sintich)

Docket No.: 30847/2051-004  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Anna Helgadottir et al.

Application No.: 10/769,744

Filed: January 30, 2004

For: SUSCEPTIBILITY GENE FOR  
MYOCARDIAL INFARCTION, STROKE,  
AND PAOD; METHODS OF TREATMENT

Confirmation No.: 6429

Art Unit: 1634

Examiner: D. Johannsen

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the reference listed on the attached Form PTO-1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference be made of record therein and appear among the "References Cited" on any patent to issue therefrom. A copy of document C134 is enclosed.

In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art."

This Supplemental Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37

Application No.: 10/769,744


Docket No.: 30847/2051-004

CFR 1.97(b)(3)). Accordingly, no fees are believed to be due. However, the Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 30847/2051-004. A duplicate copy of this paper is enclosed.

Dated: May 3, 2007

Respectfully submitted,

By



Sharon M. Sintich

Registration No.: 48,484

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Agent for Applicants

Form PTO-1449 (Modified)

Atty. Docket No.

30847/2051-004

Serial No.

10/769,744

**INFORMATION DISCLOSURE STATEMENT**

Applicant(s)

Anna Helgadottir et al.

Filing Date

January 30, 2004

Art Unit

1634

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Issue or Publication Date	Name	Class	Subclass	Filing Date (If Appropriate)

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Document Number	Publication Date	Country	Translation Yes      No	

**OTHER DOCUMENTS**

C134	Morgan <i>et al.</i> , Nonvalidation of Reported Genetic Risk Factors for Acute Coronary Syndrome in a Large-Scale Replication Study, <i>J. Amer. Med. Assoc.</i> , 297: 1551-1561 (April 11, 2007).
------	--

EXAMINER:

DATE CONSIDERED: